Mark L. Fuerst

Oncology professionals share what #MedTwitter means to them and where they might go if Twitter (now X) becomes obsolete.

Most patients had at least 1 biomarker test, but only 46% had all 5 biomarker tests.

Researchers found that CROSS is not inferior to MAGIC/FLOT, supporting it’s place in decision making for patients with locally advanced esophageal cancer.

Researchers have identified a potentially new first-line treatment option for patients with advanced or metastatic esophageal squamous cell carcinoma.

Nivolumab plus chemotherapy improved overall survival.

Adjuvant nivolumab prolonged distant metastasis-free survival.